![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Molecular Physiology and Biophysics, Center for Molecular Neuroscience, Vanderbilt University, Nashville, Tennessee (B.G.G., Y.W., J.A.M., A.G.); Departments of Medicine and Physiology, State University of New York at Stony Brook, Stony Brook, New York (R.Z.L.); and Departments of Psychiatry and Pharmacology, Center for Molecular Recognition, College of Physicians and Surgeons, Columbia University, New York, New York (J.A.J.)
Uptake by the dopamine transporter (DAT) is the primary pathway for the clearance of extracellular dopamine (DA) and consequently for regulating the magnitude and duration of dopaminergic signaling. Amphetamine (AMPH) has been shown to decrease simultaneously DAT cell-surface expression and [3H]DA uptake. We have shown that insulin and its subsequent signaling through the phosphatidylinositol 3-kinase (PI3K)-dependent pathway oppose this effect of AMPH by promoting increased cell-surface expression. Here, we used human embryonic kidney 293 cells stably expressing the human DAT (hDAT cells) to investigate the downstream cellular components important for this effect of insulin. Akt is a protein kinase effector immediately downstream of PI3K. Both overexpression of a dominant-negative mutant of Akt (K179R) and the addition of 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine HCl (ML9), a pharmacological inhibitor of Akt, decreased cell-surface expression of DAT, suggesting a role of basal Akt signaling in the homoeostasis of DAT. Moreover, expression of a constitutively active Akt mutant reduced the ability of AMPH to decrease hDAT cell-surface expression as well as [3H]DA uptake. In contrast, overexpression of K179R blocked the ability of insulin to oppose AMPH-induced reduction of hDAT cell-surface expression and [3H]DA uptake, as did ML9. Our data demonstrate that hDAT cell-surface expression is regulated by the insulin signaling pathway and that Akt plays a key role in the hormonal modulation of AMPH-induced hDAT trafficking and in the regulation of basal hDAT cell-surface expression.
Address correspondence to: Dr. Aurelio Galli, Department of Molecular Physiology and Biophysics, Center for Molecular Neuroscience, Vanderbilt University, 465 21st Avenue South, Nashville, TN 37232-8548. E-mail: aurelio.galli{at}vanderbilt.edu
This article has been cited by other articles:
![]() |
A. Hajnal, N. K. Acharya, P. S. Grigson, M. Covasa, and R. C. Twining Obese OLETF rats exhibit increased operant performance for palatable sucrose solutions and differential sensitivity to D2 receptor antagonism Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1846 - R1854. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Anderzhanova, M. Covasa, and A. Hajnal Altered basal and stimulated accumbens dopamine release in obese OLETF rats as a function of age and diabetic status Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R603 - R611. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, J. M. Williams, C. Dipace, U. Sung, J. A. Javitch, A. Galli, and C. Saunders Dopamine Transporter Activity Mediates Amphetamine-Induced Inhibition of Akt through a Ca2+/Calmodulin-Dependent Kinase II-Dependent Mechanism Mol. Pharmacol., March 1, 2007; 71(3): 835 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dipace, U. Sung, F. Binda, R. D. Blakely, and A. Galli Amphetamine Induces a Calcium/Calmodulin-Dependent Protein Kinase II-Dependent Reduction in Norepinephrine Transporter Surface Expression Linked to Changes in Syntaxin 1A/Transporter Complexes Mol. Pharmacol., January 1, 2007; 71(1): 230 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Kahlig, B. J. Lute, Y. Wei, C. J. Loland, U. Gether, J. A. Javitch, and A. Galli Regulation of Dopamine Transporter Trafficking by Intracellular Amphetamine Mol. Pharmacol., August 1, 2006; 70(2): 542 - 548. [Abstract] [Full Text] [PDF] |
||||